970462-5

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau IPOS

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 233/54, A61K 31/415, C07D 401/06, 401/12, 401/14, 403/12 — A1

(11) International Publication Number: WO 96/10018

(43) International Publication Date: 4 April 1996 (04.04.96)

(21) International Application Number: PCT/US95/12272

(22) International Filing Date: 26 September 1995 (26.09.95)

(30) Priority Data:

08/313,435	27 September 1994 (27.09.94)	US
08/401,201	9 March 1995 (09.03.95)	US

(60) Parent Applications or Grants

(63) Related by Continuation

US 08/313,435 (CIP) Filed on 27 September 1994 (27.09.94)

US 08/401,201 (CIP) Filed on 9 March 1995 (09.03.95)

(71) Applicant *(for all designated States except US)*: NEUROGEN CORPORATION [US/US]; 35 N.E. Industrial Road, Branford, CT 06405 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: THURKAUF, Andrew [US/US]; 6 Foxbridge Village Road, Branford, CT 06405 (US). HUTCHISON, Alan [US/US]; 175 Bartlett Drive, Madison, CT 06443 (US).

(74) Agents: SARUSSI, Steven, J. et al.; Banner & Allegretti, Ltd., Ten South Wacker Drive, Chicago, IL 60606 (US).

(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).

Published


With international search report.


Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.


(54) Title: CERTAIN AMINOMETHYL PHENYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS

(57) Abstract

This invention encompasses compounds of formula (I) where R_1, R_3, R_4, R_6, X, Y, and Z and T are variables; and M is (a) or (b) where R_2 is a variable; or R_1 and R_2 together may represent $-(CH_2)_{n1}$ where n1 is 1, 2 or 3. These compounds are highly selective partial agonists or antagonists at brain dopamine receptor subtypes or prodrugs thereof and are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism. Furthermore, compounds of this invention may be useful in treating the extraparamidyl side effects associated with the use of conventional neuroleptic agents.







Compound 1